Testosterone products available in Canada: the 2026 list

Thirteen testosterone products were marketed in Canada on 14 September 2026, verified in Health Canada’s Drug Product Database. They cover four forms: 1 percent transdermal gel, nasal gel, oral undecanoate capsules and two short-acting intramuscular injections. Two familiar injectable brands, Delatestryl and Depo-Testosterone, were cancelled in 2025 and are no longer available.

Key takeaways

• Health Canada’s Drug Product Database listed 13 marketed human testosterone drug identification numbers on 14 September 2026, spread across six gels, one nasal gel, four oral capsules and two injections.
• Delatestryl (DIN 00029246) was cancelled post market on 18 December 2025 and Depo-Testosterone (DIN 00030783) on 18 July 2025, so Canadian content that still names either as a current option is out of date.
• Four more products are approved and not yet marketed: three Kyzatrex oral capsule strengths (DINs 02562723, 02562731, 02562758, approved 30 June and 2 July 2026) and a SteriMax testosterone cypionate injection (DIN 02570122, approved 20 July 2026).
• Canada has no testosterone cream at any status in the database, no patch since the second Androderm DIN was cancelled on 14 April 2022, and no long-acting testosterone undecanoate injection has ever been authorized here.
• Testosterone is listed in Schedule IV of the Controlled Drugs and Substances Act, item 23, sub-item (40), so every product below is a prescription controlled drug.

Everything on this page describes what a regulator has authorized, not who should take it. The treatment evidence behind these products applies to men with confirmed low testosterone, and it does not apply to men whose levels are normal. How that diagnosis is made in Canada is covered in how low testosterone is diagnosed in Canada. What testing your own case needs is a decision for your doctor or nurse practitioner.

Which testosterone products are marketed in Canada?

Thirteen, as verified in Health Canada’s Drug Product Database on 14 September 2026. Each row below is a separate drug identification number, which is why a single brand can appear more than once: the database assigns a DIN to each strength and package presentation, not to each brand.

Three points follow from the table. Every transdermal product in Canada is a 1 percent gel; there is no 1.62 percent or 2 percent gel here. Every testosterone undecanoate DIN in Canada is an oral capsule. And the injectable list is down to one cypionate and one enanthate, both generics, with no brand injectable remaining. What the esters themselves do is covered in testosterone esters explained, and the oral capsules are covered in oral testosterone evidence.

Why does one brand have several DINs?

Because a DIN identifies a specific product, strength and presentation. AndroGel holds three: two sachet sizes and a metered pump. Jatenzo holds three, one for each capsule strength. Taro-Testosterone Gel holds two. Counting brands gives a smaller number than counting DINs, and regulators count DINs.

Which testosterone products are approved in Canada but not yet available?

Four, as of 14 September 2026, and approved is not the same as available. A product with a DIN in approved status has passed Health Canada review but has not been placed on the Canadian market, so a prescription for it cannot be filled from Canadian stock.

• Kyzatrex oral testosterone undecanoate capsules, 100 mg, 150 mg and 200 mg, from Hikma, DINs 02562723, 02562731 and 02562758, approved on 30 June and 2 July 2026.
• Testosterone Cypionate Injection USP 100 mg/mL from SteriMax, DIN 02570122, approved 20 July 2026.

Marketing status can change without notice in either direction, which is why the date on this page matters as much as the list. A reader checking the database on a later date may find these four in marketed status, or may not.

Which Canadian testosterone products have been cancelled or gone dormant?

Ten drug identification numbers, and this is where most out-of-date Canadian writing goes wrong. Two of the cancellations happened in 2025, recently enough that a great deal of existing content still names the products as live options.

The two 2025 cancellations are the ones to watch for. Between 18 July and 18 December 2025 Canada lost both of its brand injectables. What replaced them is not a new product but a pair of generics, the Taro cypionate (DIN 02496003) and the Hikma enanthate (DIN 02536315), both already in the marketed table above.

The Depo-Testosterone product monograph, revised 12 July 2018, remains a published Health Canada document even though the DIN is cancelled. A monograph on file is a historical record of an approved label, not evidence that the product is on the shelf.

What testosterone forms does Canada not have at all?

Seven, and each is worth stating plainly because international articles routinely describe forms Canadians cannot obtain. All seven were checked in the Drug Product Database on 14 September 2026.

• No cream, ever. No testosterone cream dosage form appears in the Drug Product Database at any status, past or present. The only registered testosterone cream for men among the four countries reviewed is Australian.
• No patch since 2022. Androderm’s two Canadian DINs were cancelled on 13 December 2021 and 14 April 2022. In the United States, the Orange Book entries for the 2 mg and 4 mg strengths carry a Federal Register determination that the product “was not discontinued or withdrawn for safety or effectiveness reasons.” That is an American record, and no equivalent Canadian statement was found.
• No long-acting testosterone undecanoate injection, ever authorized. Nebido and Aveed have never held a Canadian authorization. Every testosterone undecanoate DIN in Canada is an oral capsule.
• No mixed-ester injection. There is no Sustanon-type four-ester product in Canada.
• No subcutaneous auto-injector. Xyosted is authorized in the United States only.
• No implantable pellets. They have never been marketed in Canada.
• No 2 percent topical solution. Axiron, DIN 02382369, was cancelled on 4 December 2017 and nothing replaced it.

The gels, the nasal gel and the less common routes are covered in more detail in testosterone gels and creams and in nasal, buccal and pellet testosterone. How Canada’s list compares with three other countries is set out in testosterone products by country.

Is a product reported short right now?

Being marketed is not the same as being on a pharmacy shelf. Injectable testosterone has been reported short in Canada repeatedly since 2019, and both long-standing injectable brands, Depo-Testosterone and Delatestryl, are now recorded as cancelled post market, leaving one marketed cypionate injection and one marketed enanthate injection. The shortages page keeps three questions apart: whether a product is marketed (a Health Canada database status), whether its company has reported a shortage or discontinuation to Health Product Shortages Canada (with the dates and the reason given), and whether a particular pharmacy or provider has it in stock (which only that pharmacy or provider can say, and which the page records as each provider publishes it, on the same terms for everyone). It also sets out, from Trans Care BC and the Canadian Society of Endocrinology and Metabolism, what to ask your pharmacist and prescriber if your product is short, and why a switch between products is a new prescription rather than a change of volume. Where nothing is published or stale, the page says not confirmed, not unavailable.

How can a reader check this list independently?

Through the same public database this page was built from. Every entry above was verified in Health Canada’s Drug Product Database on 14 September 2026 at https://health-products.canada.ca/dpd-bdpp/search/, which is free, searchable by brand, DIN or ingredient, and shows current status including marketed, approved, cancelled post market and dormant.

Search the ingredient “testosterone” and filter by status rather than searching a brand name, because a cancelled brand still returns a record. The status field, not the presence of a record, is what tells a reader whether a product exists on the Canadian market today.

Where does testosterone sit in Canadian drug law?

In Schedule IV of the Controlled Drugs and Substances Act. Item 23 of that schedule covers anabolic steroids and their derivatives, and sub-item (40) is testosterone. Every product on this page is therefore both a prescription drug and a controlled substance, which is why supply, record keeping and refills are handled differently from an ordinary prescription.

Canadian product monographs still describe testosterone as a “Schedule G controlled substance as defined by the Food and Drugs Act.” That is legacy wording from an earlier framework. Both phrasings appear in Canadian documents and the statute is the current authority. The wider regulatory picture, including the fact that Health Canada has issued nothing on testosterone since its Information Update of 15 July 2014, is set out in testosterone rules in Canada, the US, Europe and Australia.

What about compounded testosterone?

A compounded preparation has no DIN, so it does not appear anywhere in the list above. Health Canada’s policy POL-0051 states that “compounding of drugs is practised primarily by pharmacists as an integral part of their profession and is regulated by the respective regulatory authorities in each province/territory,” which places oversight with the provincial college rather than with Health Canada. That distinction, and the thin evidence base behind it, is covered in compounded testosterone in Canada.

What the evidence does not show

• The Drug Product Database records regulatory status, not supply. A product in marketed status can still be back-ordered or unavailable at a given pharmacy, and the database will not say so.
• Approved status is not availability. The three Kyzatrex capsule strengths and the SteriMax cypionate, DIN 02570122, were approved between 30 June and 20 July 2026 and were still not marketed on 14 September 2026.
• No public reason could be found for why long-acting testosterone undecanoate injection has never been authorized in Canada, or for why no testosterone cream for men has ever been registered here. Both are best recorded as no public reason on record rather than explained by a guess.
• Nothing in this list ranks the products. There is no head-to-head pharmacokinetic or clinical trial comparing testosterone cypionate with testosterone enanthate by the same route, so the two remaining Canadian injectables have never been tested against each other.
• A list of authorized products carries no information about whether treatment is appropriate for any individual, and the presence of a DIN says nothing about whether a person’s testosterone is low.

Frequently asked questions

How many testosterone products are marketed in Canada?

Thirteen human drug identification numbers held marketed status in Health Canada’s Drug Product Database on 14 September 2026. They break down as six 1 percent transdermal gels across three brands, one nasal gel, four oral capsules across two brands, one intramuscular cypionate and one intramuscular enanthate. Counting brands rather than DINs gives a smaller figure, because several brands hold multiple DINs.

Is Depo-Testosterone still available in Canada?

No. Depo-Testosterone, testosterone cypionate 100 mg/mL from Pfizer, DIN 00030783, was cancelled post market on 18 July 2025. The only cypionate in marketed status in Canada on 14 September 2026 was Taro-Testosterone Cypionate Injection 100 mg/mL, DIN 02496003. A second cypionate from SteriMax, DIN 02570122, was approved on 20 July 2026 but was not yet marketed.

Is Delatestryl still available in Canada?

No. Delatestryl, testosterone enanthate 200 mg/mL from Bausch Health, DIN 00029246, was cancelled post market on 18 December 2025. The enanthate in marketed status on 14 September 2026 was Testosterone Enanthate Injection USP 200 mg/mL from Hikma Canada, DIN 02536315. Canadian articles written before December 2025 that name Delatestryl as a current option are out of date.

Can you get a testosterone patch or cream in Canada?

No to both. The two Androderm patch DINs, 02239653 and 02245972, were cancelled on 14 April 2022 and 13 December 2021, and no patch has been marketed in Canada since. No testosterone cream dosage form appears in the Drug Product Database at any status, past or present, so Canada has never had one. Both checks were made on 14 September 2026.

Does Canada have long-acting testosterone undecanoate injection?

No, and it never has. Nebido and Aveed, the long-acting castor oil depot products used elsewhere, have never held a Canadian authorization. Every testosterone undecanoate drug identification number in Canada is an oral capsule, verified in the Drug Product Database on 14 September 2026. No public reason for the absence could be found in Health Canada’s published record.

What is the difference between approved and marketed?

Approved means Health Canada has reviewed the product and issued a drug identification number. Marketed means the company has actually placed it on the Canadian market. A prescription cannot be filled from Canadian stock for an approved product that is not marketed. On 14 September 2026 four testosterone DINs sat in that gap: three Kyzatrex capsule strengths and one SteriMax cypionate.

Update, 23 September 2026: the marketed count was unchanged at thirteen when every DIN on this page was read again. One new DIN has joined the approved but not marketed group: Taro-Testosterone Gel Pump, testosterone 12.5 mg per actuation, DIN 02571714, approved 18 September 2026.

Do compounded testosterone preparations have a DIN?

No. Compounded preparations are made for an individual patient and carry no drug identification number, so they appear nowhere in the marketed, approved, cancelled or dormant lists above. Health Canada’s policy POL-0051 places compounding oversight with provincial and territorial regulatory authorities rather than with Health Canada itself.

References

1. Health Canada. Drug Product Database. Retrieved 14 September 2026. https://health-products.canada.ca/dpd-bdpp/search/
2. Government of Canada. Controlled Drugs and Substances Act, Schedule IV. Retrieved 14 September 2026. https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-12.html
3. Health Canada. Product Monograph, JATENZO (testosterone undecanoate oral capsules). Authorized 12 December 2025. https://pdf.hres.ca/dpd_pm/00082762.PDF
4. Health Canada. Product Monograph, DEPO-TESTOSTERONE (testosterone cypionate). Revised 12 July 2018. https://pdf.hres.ca/dpd_pm/00046306.PDF
5. Health Canada. Information Update, Possible cardiovascular problems associated with testosterone products. 15 July 2014. https://recalls-rappels.canada.ca/en/alert-recall/information-update-possible-cardiovascular-problems-associated-testosterone-products
6. Health Canada. Policy POL-0051, on the compounding of drugs. Verified 14 September 2026. URL not recorded in the source review.
7. US Food and Drug Administration. Drugs@FDA and the Orange Book. Retrieved 14 September 2026. https://www.accessdata.fda.gov/scripts/cder/daf/

This page is educational information, not medical advice. Testosterone is a prescription medication and a controlled substance in Canada. Talk to your doctor or pharmacist about your own situation.